Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M117Revenue (TTM) $M7.7Net Margin (%)-197.3Altman Z-Score-7.4
Enterprise Value $M74.2EPS (TTM) $-0.2Operating Margin %-198.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.0Pre-tax Margin (%)-197.3Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %-16.4Quick Ratio5.1Cash flow > EarningsN
Price/Sales13.65-y EBITDA Growth Rate %-6.7Current Ratio5.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-45.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M71.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARQL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARQLFirst Eagle Investment 2016-06-30 Add$1.43 - $1.92
($1.69)
$ 1.65-2%Add 0.12%10,837,733
ARQLFirst Eagle Investment 2016-03-31 Add0.01%$1.43 - $2.17
($1.76)
$ 1.65-6%Add 24.14%10,825,233
ARQLFirst Eagle Investment 2015-06-30 Add0.01%$1.53 - $2.26
($1.93)
$ 1.65-15%Add 52.45%8,719,968
ARQLFirst Eagle Investment 2015-03-31 Add0.01%$1.1 - $2.46
($1.59)
$ 1.654%Add 28.69%5,719,968
ARQLFirst Eagle Investment 2014-12-31 Add$1.06 - $1.36
($1.18)
$ 1.6540%Add 56.31%4,444,899
ARQLGeorge Soros 2014-09-30 Sold Out $1.12 - $1.56
($1.31)
$ 1.6526%Sold Out0
ARQLGeorge Soros 2014-06-30 Buy $1.34 - $2.04
($1.56)
$ 1.656%New holding78,600
ARQLFirst Eagle Investment 2013-09-30 Reduce-0.01%$2.15 - $2.79
($2.51)
$ 1.65-34%Reduce -26.47%3,314,553
ARQLFirst Eagle Investment 2012-12-31 Add0.01%$2.18 - $2.95
($2.6)
$ 1.65-37%Add 49.46%4,539,651
ARQLFirst Eagle Investment 2012-06-30 Add0.01%$5.53 - $8.16
($6.56)
$ 1.65-75%Add 28.79%2,673,589
ARQLGeorge Soros 2011-12-31 Sold Out -0.0014%$4.58 - $6.05
($5.55)
$ 1.65-70%Sold Out0
ARQLGeorge Soros 2011-09-30 Add$4.11 - $6.64
($5.2)
$ 1.65-68%Add 54.79%16,100
ARQLFirst Eagle Investment 2011-03-31 Add0.03%$5.85 - $6.95
($6.41)
$ 1.65-74%Add 84.22%1,693,456
ARQLGeorge Soros 2011-03-31 Buy $5.85 - $6.95
($6.41)
$ 1.65-74%New holding12,200
ARQLFirst Eagle Investment 2010-12-31 Add0.01%$4.95 - $6.14
($5.53)
$ 1.65-70%Add 29.43%919,266
ARQLFirst Eagle Investment 2010-03-31 Reduce-0.03%$3.04 - $3.92
($3.45)
$ 1.65-52%Reduce -56.47%685,266
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARQL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARQL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LOBERG MICHAEL DDirector 2015-12-17Buy3,719$2.16-23.61view
LOBERG MICHAEL DDirector 2015-12-16Buy1,231$2.14-22.9view
Pucci PaoloCEO 2015-12-15Buy1,283$2.16-23.61view
Pucci PaoloCEO 2015-12-11Buy1,108$2.1-21.43view
ZENNER PATRICK JDirector 2015-12-11Buy2,300$2.15-23.26view
Pucci PaoloCEO 2015-12-10Buy7,609$2.1-21.43view
ZENNER PATRICK JDirector 2015-03-11Buy10,625$2.32-28.88view
Pucci PaoloCEO 2014-11-20Buy5,000$1.2630.95view
ZENNER PATRICK JDirector 2014-11-14Buy20,830$1.237.5view
Messenger William GDirector 2014-11-14Buy8,500$1.2136.36view

Quarterly/Annual Reports about ARQL:

News about ARQL:

Articles On GuruFocus.com
Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 
ArQule Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September... Sep 21 2016
ETF’s with exposure to ArQule, Inc. : September 19, 2016 Sep 19 2016
ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ... Sep 15 2016
ETF’s with exposure to ArQule, Inc. : September 8, 2016 Sep 08 2016
ETF’s with exposure to ArQule, Inc. : August 25, 2016 Aug 25 2016
ETF’s with exposure to ArQule, Inc. : August 11, 2016 Aug 11 2016
ARQULE INC Financials Aug 06 2016
ArQule, Inc. :ARQL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 Aug 05 2016
Edited Transcript of ARQL earnings conference call or presentation 3-Aug-16 1:00pm GMT Aug 03 2016
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 03 2016
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 Aug 03 2016
ArQule reports 2Q loss Aug 03 2016
ArQule reports 2Q loss Aug 03 2016
Q2 2016 ArQule Inc Earnings Release - Before Market Open Aug 03 2016
ArQule Reports Second Quarter 2016 Financial Results Aug 03 2016
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 Jul 20 2016
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and... Jul 18 2016
ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016 Jul 05 2016
Here’s What The ArQule, Inc. (ARQL) Data Really Means Jul 01 2016
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity... Jun 30 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)